Globalstar vs Merck & Co., Inc. — how do they compare? Globalstar trades at $83.52 (market cap $10.78B), while Merck & Co., Inc. trades at $144.77 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 32.6× Globalstar's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Globalstar pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globalstar for 20 Days and Merck & Co., Inc. for 98 Days on average.
| GSAT | MRK | |
|---|---|---|
Market Cap | $10.78B | $351.28B |
Volume | 723,953 | 7,969,665 |
Sector | Media | Health |
52-Week High | $84.43 | $156.43 |
52-Week Low | $41.54 | $82.49 |
Typical Hold Time | 20 Days | 98 Days |
Enterprise Value | $10.79B | $398.04B |
Dividend Yield | — | 2.39% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globalstar provides satellite and terrestrial connectivity services, including voice, data, asset tracking, and private wireless solutions. It operates a low-Earth-orbit satellite network and holds licensed mid-band spectrum.
Read more on GSAT →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →